imetelstat
3 abstracts
Abstract
Efficacy of imetelstat on red blood cell (RBC)-transfusion independence (TI) in the absence of platelet transfusions or myeloid growth factors in IMerge.Org: Yale University, Azienda Ospedaliero Universitaria Careggi, University of Florence, University of Florence, AOUC, Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, University Hospital Leipzig,
Abstract
Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial.Org: Marien Hospital Düsseldorf, Cancer Center IRCCS Humanitas Research Hospital, IRCSS Azienda Ospedaliera Universitaria di Bologna, MDS Unit, Service d'Hématologie Séniors,
Abstract
IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA).Org: Yale School of Medicine and Yale Cancer Center, Yale University, Leipzig University Hospital, Azienda Ospedaliero Universitaria Careggi, University of Florence, Hôpital Saint-Louis, Université de Paris, Sylvester Comprehensive Cancer Center, University of Miami Health System,